BioXcel Therapeutics Stock Jumps 24% After FDA Nod for Bipolar Treatment Course
(BioXcel) Shares of BioXcel Therapeutics rose more than 24% in premarket on Tuesday after saying its treatment course for Bipolar I and II disorders in adults was approved by FDA.…